A Prospective Study of the Incidence of Juvenile-Onset Recurrent Respiratory Papillomatosis After Implementation of a National HPV Vaccination Program

Novakovic, Daniel; Cheng, Alan; Zurynski, Yvonne; Booy, Robert; Walker, Paul; Berkowitz, Robert G.; Harrison, Henley C.; Black, Robert J.; Perry, Christopher; Vijayasekaran, Shyan; Wabnitz, David; Burns, Hannah; Tabrizi, Sepehr N.; Garland, Suzanne M.; Elliott, Elizabeth J; Brotherton, Julia

doi:10.1093/infdis/jix498

Cited by 75 publications

(64 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nevertheless, several initiatives are exploring the incidence of RRP as a function of qHPV vaccination at the population level. Data from Australia has shown a reduction in the incidence of juvenile-onset RRP after implementation of the National HPV Vaccination Program [42]. Such data is compatible with, and therefore supportive of, our previously-held reasonable expectation that vaccination has the potential to prevent this devastating disease.…”

Section: Plos Onesupporting

confidence: 81%

In RRP, serologic response to HPV is frequently absent and slow to develop

et al. 2020

View full text Add to dashboard Cite

BackgroundRecurrent respiratory papillomatosis (RRP) is characterized by repeated formation of papillomas in the respiratory tract and is caused by human papillomavirus (HPV) types 6 and 11. Women with genital HPV infection are slow to develop weak humoral immunity, but respond robustly to the HPV vaccine. We wondered if people with RRP had a similar immune response. MethodsA convenience cross-sectional sample of patients with RRP were recruited into one of four groups: 1) adults and adolescents with active RRP, 2) children with active RRP, 3) RRP patients who had undergone HPV vaccination prior to enrollment and, 4) people with RRP who were in remission. Anti-HPV6 and HPV11 serology was determined by cLIA on a single blood draw. OPEN ACCESS Citation: Buchinsky FJ, Ruszkay N, Valentino W, Derkay CS, McClay JE, Bastian RW, et al. (2020) In RRP, serologic response to HPV is frequently absent and slow to develop. PLoS ONE 15(3): e0230106. https://doi. ConclusionPeople with RRP are capable of developing a humoral response to HPV6 and HPV11. That response appears to be robust when initiated by the HPV vaccine, but either nonexistent or slow to develop in response to infection. Most in remission do not have demonstrable antibody levels against HPV6 or HPV11.

show abstract

Section: Plos Onesupporting

confidence: 81%

In RRP, serologic response to HPV is frequently absent and slow to develop

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Since the introduction of the HPV vaccination program, Australia has observed remarkable reductions in HPV infection, genital warts, cervical precancers and most recently recurrent respiratory papillomatosis. 42 that Aboriginal and Torres Strait Islander people are benefitting as much as non-Indigenous Australians from the program.…”

Section: Discussionmentioning

confidence: 99%

Vaccine Preventable Diseases and Vaccination Coverage in Aboriginal and Torres Strait Islander People, Australia, 2011–2015

2019

View full text Add to dashboard Cite

Restrictions The Licence does not cover, and there is no permission given for, use of any of the following material found in this publication (if any): • the Commonwealth Coat of Arms (by way of information, the terms under which the Coat of Arms may be used can be found at www.itsanhonour.gov.au); • any logos (including the Department of Health's logo) and trademarks; • any photographs and images; • any signatures; and • any material belonging to third parties. Disclaimer Opinions expressed in Communicable Diseases Intelligence are those of the authors and not necessarily those of the Australian Government Department of Health or the Communicable Diseases Network Australia. Data may be subject to revision. Enquiries Enquiries regarding any other use of this publication should be addressed to the Communication Branch,

show abstract

“…Epidemiologischen Studien zufolge könnte durch diese Maßnahme die jährliche Neuerkrankungsrate an Zervixkarzinomen deutlich reduziert werden [48]. Erste Daten zur Inzidenz der RRP belegen, dass auch diese nach Einführung der Impfung jährlich rückläufig ist [49], sodass zukünftig möglicherweise die Therapie der RRP zugunsten der Prophylaxe in den Hintergrund treten wird.…”

Section: Ausblick Und Schlussfolgerungunclassified